<img alt="" src="https://secure.hero6bell.com/211997.png" style="display:none;">
Investor relations

EGM September 2019

The following persons are proposed for election to the Board of Directors

Peter von Ehrenheim

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Education: M.Sc. in Mechanical Engineering

Thomas Eklund

Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Education: MBA Stockholm School of Economics

Protokoll extra bolagsstämma